TUL Completes Phase II Trial of TUL01101 Tablets for Atopic Dermatitis

Reuters11-10

TUL Completes Phase II Trial of TUL01101 Tablets for Atopic Dermatitis

The United Laboratories International Holdings Ltd. (TUL) has announced the completion of a Phase II clinical trial for its investigational drug, TUL01101 Tablets, in adult patients with moderate-to-severe atopic dermatitis in China. The multicenter, randomized, double-blind, placebo-controlled study enrolled 201 subjects who received TUL01101 Tablets in three dose groups (20 mg, 40 mg, and 60 mg) or placebo once daily for 12 weeks. The trial was designed to evaluate the efficacy, safety, tolerability, and pharmacokinetic characteristics of the drug. According to the company, the trial achieved its expected objectives, supporting advancement to the next stage of clinical development. TUL is currently initiating a Phase III clinical trial for TUL01101 Tablets in the same patient population. The results of the Phase II trial have already been completed and disclosed in this announcement. TUL01101 Tablets is described as a highly selective JAK1 inhibitor, with ongoing clinical development for atopic dermatitis and rheumatoid arthritis.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TUL - The United Laboratories International Holdings Ltd. published the original content used to generate this news brief on November 10, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2582870674?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-10 22:56","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2582870674","market":"fut","top_or_hot":-1,"title":"TUL Completes Phase II Trial of TUL01101 Tablets for Atopic Dermatitis","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      TUL Completes Phase II Trial of TUL01101 Tablets for Atopic Dermatitis\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        The <a href=\"https://laohu8.com/S/ULIHF\">United Laboratories International Holdings Ltd.</a> (TUL) has announced the completion of a Phase II clinical trial for its investigational drug, TUL01101 Tablets, in adult patients with moderate-to-severe atopic dermatitis in China. The multicenter, randomized, double-blind, placebo-controlled study enrolled 201 subjects who received TUL01101 Tablets in three dose groups (20 mg, 40 mg, and 60 mg) or placebo once daily for 12 weeks. The trial was designed to evaluate the efficacy, safety, tolerability, and pharmacokinetic characteristics of the drug. According to the company, the trial achieved its expected objectives, supporting advancement to the next stage of clinical development. TUL is currently initiating a Phase III clinical trial for TUL01101 Tablets in the same patient population. The results of the Phase II trial have already been completed and disclosed in this announcement. TUL01101 Tablets is described as a highly selective JAK1 inhibitor, with ongoing clinical development for atopic dermatitis and rheumatoid arthritis.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TUL - The United Laboratories International Holdings Ltd. published the original content used to generate this news brief on November 10, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>TUL Completes Phase II Trial of TUL01101 Tablets for Atopic Dermatitis</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTUL Completes Phase II Trial of TUL01101 Tablets for Atopic Dermatitis\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-10 22:56</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      TUL Completes Phase II Trial of TUL01101 Tablets for Atopic Dermatitis\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        The <a href=\"https://laohu8.com/S/ULIHF\">United Laboratories International Holdings Ltd.</a> (TUL) has announced the completion of a Phase II clinical trial for its investigational drug, TUL01101 Tablets, in adult patients with moderate-to-severe atopic dermatitis in China. The multicenter, randomized, double-blind, placebo-controlled study enrolled 201 subjects who received TUL01101 Tablets in three dose groups (20 mg, 40 mg, and 60 mg) or placebo once daily for 12 weeks. The trial was designed to evaluate the efficacy, safety, tolerability, and pharmacokinetic characteristics of the drug. According to the company, the trial achieved its expected objectives, supporting advancement to the next stage of clinical development. TUL is currently initiating a Phase III clinical trial for TUL01101 Tablets in the same patient population. The results of the Phase II trial have already been completed and disclosed in this announcement. TUL01101 Tablets is described as a highly selective JAK1 inhibitor, with ongoing clinical development for atopic dermatitis and rheumatoid arthritis.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TUL - The United Laboratories International Holdings Ltd. published the original content used to generate this news brief on November 10, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03933","symbol_name":"联邦制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nNDL7sqBRB:1","article_id":"2582870674","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2582870674","pubTimestamp":1762786614,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"The United Laboratories International Holdings Ltd.  has announced the completion of a Phase II clinical trial for its investigational drug, TUL01101 Tablets, in adult patients with moderate-to-severe atopic dermatitis in China. The multicenter, randomized, double-blind, placebo-controlled study enrolled 201 subjects who received TUL01101 Tablets in three dose groups  or placebo once daily for 12 weeks. The trial was designed to evaluate the efficacy, safety, tolerability, and pharmacokinetic characteristics of the drug. According to the company, the trial achieved its expected objectives, supporting advancement to the next stage of clinical development. TUL is currently initiating a Phase III clinical trial for TUL01101 Tablets in the same patient population. The results of the Phase II trial have already been completed and disclosed in this announcement. TUL01101 Tablets is described as a highly selective JAK1 inhibitor, with ongoing clinical development for atopic dermatitis and rhe","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03933":"联邦制药","BK1191":"制药"},"translate_title":"TUL完成TUL01101片治疗特应性皮炎的II期试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03933":0.9},"content_text":"TUL Completes Phase II Trial of TUL01101 Tablets for Atopic Dermatitis\n    \n\n        The United Laboratories International Holdings Ltd. (TUL) has announced the completion of a Phase II clinical trial for its investigational drug, TUL01101 Tablets, in adult patients with moderate-to-severe atopic dermatitis in China. The multicenter, randomized, double-blind, placebo-controlled study enrolled 201 subjects who received TUL01101 Tablets in three dose groups (20 mg, 40 mg, and 60 mg) or placebo once daily for 12 weeks. The trial was designed to evaluate the efficacy, safety, tolerability, and pharmacokinetic characteristics of the drug. According to the company, the trial achieved its expected objectives, supporting advancement to the next stage of clinical development. TUL is currently initiating a Phase III clinical trial for TUL01101 Tablets in the same patient population. The results of the Phase II trial have already been completed and disclosed in this announcement. TUL01101 Tablets is described as a highly selective JAK1 inhibitor, with ongoing clinical development for atopic dermatitis and rheumatoid arthritis.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TUL - The United Laboratories International Holdings Ltd. published the original content used to generate this news brief on November 10, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.10","shortVersion":"4.35.10","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2582870674","isCrawlerRequest":true}